

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare
醫思健康

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (“**Directors**”) of EC Healthcare (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mrs. Leung Yang, Shih Ti Marianne (with former name Yang, Shih Ti Marianne) (“**Mrs. Leung**”) has been appointed as a non-executive Director of the Company with effect from 27 December 2024.

The biographical details of Mrs. Leung are set out as follow:

Mrs. Leung, aged 70, is currently a director at PathLab Medical Laboratories Limited (“**PathLab**”), a wholly-owned subsidiary of the Group. Mrs. Leung has headed and directed PathLab (formerly known as Sing Tao Medical Laboratory Limited) since 1982 and currently oversees its operations, management, and strategy implementation. PathLab is one of the largest private laboratories in Hong Kong and has been in operation for over 49 years. In 2006, PathLab was the first private laboratory to become ISO 15189 accredited for clinical laboratory testing in Hong Kong.

Mrs. Leung received a Bachelor of Science degree (BS, MT, ASCP) from Creighton University in the United States. She is a qualified medical technologist in both Hong Kong and the United States and has dedicated her entire career to the medical laboratory industry. Mrs. Leung has held and still holds positions on various laboratory-related committees of HKSAR Government and higher educational institutions. She was a member of the Hong Kong Medical Laboratory Technologist Board (2007 to 2013) and the Hong Kong Council for Testing and Certification (2009 to 2016). In 2022, during the COVID-19 epidemic, she was awarded the Chief Executive’s Commendation for Community Service.

Mrs. Leung has entered into a letter of appointment with the Company for a term of 3 years commencing on 27 December 2024. She is also subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment, Mrs. Leung is entitled to receive a remuneration of HK\$120,000 per annum. Her remuneration package is determined by the Board based on the recommendation of the remuneration committee of the Company, taking into account the remuneration paid by comparable companies, time

commitment, duties and responsibilities of Mrs. Leung, the Company's performance and profitability, the remuneration policy and prevailing market rate.

As at the date of this announcement, Mrs. Leung owns, through Sunny Sea Global Limited (a company beneficially owned by herself and her spouse as to 50% and 50% respectively), 5,500,000 shares of the Company. Mrs. Leung also personally owns 2,183,000 shares of the Company, which are used as investment shares in the Co-ownership Plan 2 of the Company. Save for the aforesaid, Mrs. Leung does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mrs. Leung does not (i) hold any other position with the Company or any other members of the Group; (ii) have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company (each as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")); (iii) hold any other directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; and (iv) have other major appointments and professional qualifications.

Save as disclosed above, the Board is not aware of any other information to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters concerning the appointment of Mrs. Leung as non-executive Director that need to be brought to the attention of the holders of securities of the Company.

The Board would like to take this opportunity to extend a warm welcome to Mrs. Leung for joining the Company.

The Company had a female director in the past, who has resigned on 1 November 2023 and the Company should appoint a female director within 3 months thereafter. However, the Company did not comply with the same since it has mis-interpreted Rule 13.92 of the Listing Rules and considered that it could achieve gender diversity on or before 31 December 2024 in accordance with the note of Rule 13.92 of the Listing Rules.

By Order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 27 December 2024

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie and Mr. Lee Heung Wing; the non-executive Directors are Mr. Luk Kun Shing Ben and Mrs. Leung Yang, Shih Ti Marianne; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.